MRK vs TNGX
Merck & Co. vs Tango Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TNGX
Tango Therapeutics, Inc.
55
Buy
| Metric | MRK | TNGX |
|---|
| AI Score |
70
|
55
|
| Price |
$130.34
|
$26.32
|
| P/E Ratio |
103.53×
|
-30.99×
|
| ROE |
34.7%
|
-29.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
98.2%
|
| Debt / Equity |
1.29×
|
0.03×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
38.9
|
| Beta |
0.207
|
1.127
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus TNGX.
MRK leads by 15 points.
MRK scores 70/100 (Buy) versus TNGX at 55/100 (Buy).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TNGX Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 16.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.2% signals elevated volatility — Risk
- No news coverage in the last 14 days -- limited independent confirmation either way — News